20/20 Biolabs, Inc. Common Stock

20/20 BioLabs announced that its management team participated in BIO Asia-Taiwan and held strategic meetings in Taipei, Tokyo, and Seoul to advance an East Asia roll-up strategy. The company is evaluating merger, acquisition, licensing, joint venture, and commercial partnership opportunities with regional firms whose products, customer relationships, data assets, laboratory infrastructure, or technology platforms may complement its mission of early detection and prevention of cancers and chronic diseases. CEO Jonathan Cohen stated that relationships in the region provided the technical foundation for its multi-cancer early detection blood test and may support the goal of achieving Medicare reimbursement for MCED by the end of 2028. The meetings focused on companies with recurring customer relationships, real-world testing data, and commercial infrastructure that could expand access to OneTest for Cancer, OneTest for Longevity, CLIAx, or related AI-enabled laboratory services. There can be no assurance that these discussions will result in any definitive agreement or transaction.

20/20 BioLabs has entered into a standstill agreement with Streeterville Capital that temporarily restricts conversions of its Series E Convertible Preferred Stock into common stock below a defined price threshold, mitigating potential near-term dilution. Under the agreement effective July 16, 2026, Streeterville agreed not to convert any Series E preferred shares during a 120-day period unless the common stock trades at least 10% above the Minimum Price as defined under Nasdaq Rule 5635. The standstill terminates immediately upon any breach of the agreement or an event of default under the Series E preferred stock terms. Upon expiration or termination, Streeterville may resume conversions according to the original transaction documents, which otherwise remain in full force and effect.

20/20 BioLabs outlined its strategy to position OneTest™ for Cancer as an affordable multi-cancer early detection blood test targeting Medicare reimbursement under a new statutory pathway beginning in 2028. The company emphasized that Medicare coverage would require FDA authorization and a CMS determination of clinical appropriateness, neither of which has been obtained. OneTest™ uses a panel of protein tumor markers, inflammation-associated biomarkers, machine learning, and serial testing to track biomarker trajectories over time, which the company believes may support earlier detection and improved specificity. The company also reported that its second quarter MCED revenue is expected to be its highest to date and at least 30% higher than the prior-year second quarter, based on preliminary unaudited numbers. Additionally, more than 35,000 American firefighters are expected to have been tested by the end of 2026, providing real-world data to support regulatory and reimbursement efforts.